Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Operating Expenses for 7 years, with the latest figure at $75.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 18.99% year-over-year to $75.2 million; the trailing twelve-month figure through Mar 2026 stood at $279.0 million (up 13.84% YoY), and the FY2025 full-year result was $266.9 million, up 12.77% from the prior year.
• Operating Expenses for Q1 2026 stood at $75.2 million, up from $69.0 million in the prior quarter.
• The five-year high for Operating Expenses was $75.2 million in Q1 2026, with the low at $44.2 million in Q2 2022.
• Historically, Operating Expenses has averaged $57.6 million across 5 years, with a median of $54.9 million in 2024.
• The largest YoY upside for Operating Expenses was 105.12% in 2022 against a maximum downside of 30.68% in 2022.
• Xeris Biopharma Holdings' Operating Expenses stood at $48.3 million in 2022, then gained by 12.25% to $54.2 million in 2023, then increased by 7.72% to $58.4 million in 2024, then gained by 18.17% to $69.0 million in 2025, then rose by 8.95% to $75.2 million in 2026.
• The last three Operating Expenses figures came in at $75.2 million (Q1 2026), $69.0 million (Q4 2025), and $67.6 million (Q3 2025), per Business Quant data.